NEWS
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Citius Pharmaceuticals, a late-stage biopharmaceutical company, announced a scheduled investor call to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. The call will take place on Monday, June 3, 2024, at 8:30 AM ET. Citius Chairman and CEO, Leonard Mazur, alongside the management team, will address the trial results and the clinical need for Mino-Lok in treating catheter-related bloodstream infections. A Q&A session will follow the discussion. The conference call will be accessible via a U.S. toll-free number, an international dial-in number, and a webcast, with a replay available on the company's website for 90 days.
Citius Pharmaceuticals, a late-stage biopharmaceutical company, announced a scheduled investor call to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. The call will take place on Monday, June 3, 2024, at 8:30 AM ET. Citius Chairman and CEO, Leonard Mazur, alongside the management team, will address the trial results and the clinical need for Mino-Lok in treating catheter-related bloodstream infections. A Q&A session will follow the discussion. The conference call will be accessible via a U.S. toll-free number, an international dial-in number, and a webcast, with a replay available on the company's website for 90 days.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2565Followers
107Following
28KVisitors
Follow